Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTO-104 in Meniere's Disease
NCT02717442Phase 3Terminated
- Sponsor
- Otonomy, Inc.
- Start
- Mar 2016
- Primary completion
- Aug 2017
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Otividex in Meniere's disease (MD), sponsored by Otonomy, Inc.. Started Mar 2016; status: terminated.
02
Drugs
Otividex
03
Conditions
Meniere's disease (MD)
Beyond the preview
Go deeper on NCT02717442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02717442.